---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335212"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2026-08-05T20:22:06+00:00"
generated_at: "2026-08-05T20:23:09.494727+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences Q2 2026 revenue $48.1M (+6% YoY); net loss widens to $12.2M from $5.6M

## Summary
- Total revenue $48.1M, up 6% YoY; GAAP gross margin improved to 59% from 52%.
- Net loss $12.2M vs $5.6M loss YoY; adjusted EBITDA loss $1.5M vs positive $1.3M.
- Operating expenses rose 15% to $39.7M, driven by litigation, severance, and personnel costs.
- Full-year 2026 revenue guidance raised to $207M-$212M, midpoint up $1M.
- Launched Cytek Borealis 7-laser, 60-color cytometer; installed base reached 3,933 units.

## SEC filing metadata
- accession: 0001193125-26-335212
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2026-08-05T20:22:06+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/0001193125-26-335212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/d118986d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335212
- JSON: https://secwatch.observer/filing/0001193125-26-335212.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.